Young people with a rare condition called Juvenile Idiopathic Arthritis (JIA) are taking part in clinical research to better ...

Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the ...

Juvenile idiopathic arthritis (JIA) is a chronic inflammatory condition that affects children and is characterized by arthritis lasting for more than six weeks with an onset before the age of 16.

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

Autoimmune disorders in children can cause symptoms often mistaken for common childhood illnesses. More precise diagnoses and ...

Biologic therapy reduces TMJ inflammation in children with juvenile arthritis, according to a new study. Findings show ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...

Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...

The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...